Last updated
DBV Technologies: Product Launch
DBV Technologies submitted a Biologics License Application to the U.S. FDA for VIASKIN® Peanut Patch for children aged 4-7 years, advancing its immunotherapy product through regulatory pathway.
Source: GlobeNewswire
- Who
- DBV Technologies · Biotech & Pharma · USA
- What happened
- DBV Technologies submitted a Biologics License Application to the U.S. FDA for VIASKIN® Peanut Patch for children aged 4-7 years, advancing its immunotherapy product through regulatory pathway.
- When
- 2026-09-29
- Source
- GlobeNewswire
- So what
- DBV Technologies's launch shifts talent demand before revenue catches up.
The leadership read
DBV Technologies's launch shifts talent demand before revenue catches up. In Biotech & Pharma, taking a release to scale rewards product leaders with a commercial edge and operators who build the post-launch motion. Watch whether DBV Technologies backs it with senior go-to-market hires across Americas. That separates a platform move from a one-off.
Market context: Backdrop: a 95.4 (Cool) Talent Market Index (down 5.3 on the month) with Americas activity easing (-16.2pts).
DBV Technologies: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 31 tracked companies.
MitchelLake in this thematic
More signals across Biotech & Pharma
Product Launch · Americas
ABEC →ABEC announced the commercial launch of the ATB-2100 Advanced Therapy Bioreactor, a single-use cell expansion platform aimed at advanced therapy (cell and gene therapy) manufacturing.
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher Scientific launched Gibco CHO-K1 Catalog Panel, a cGMP-ready suite of chemically defined, animal origin-free basal and feed media in liquid and dry powder formats for CHO-K1 cell line support in biologics and biosimilars production.
Product Launch · Americas
Teva Pharmaceutical Industries Ltd. →Teva received U.S. FDA approval for DEGEVMA™ (denosumab-adet), a biosimilar to Xgeva® (denosumab), for treatment of bone complications in advanced cancer patients, giant cell tumor of bone, and hypercalcemia of malignancy.
Product Launch · Americas
ACROBiosystems →ACROBiosystems launched ACRO AIx and CHO-Direct platforms, plus GlobalLifeShip cross-border supply chain solution, positioned for AI-driven drug discovery (AIDD) workflows.
Product Launch · Americas
Bristol Myers Squibb →FDA granted accelerated approval for iberdomide (marketed as Zenbexus), a multiple myeloma treatment for relapsed or refractory patients.
Product Launch · Americas
Amgen →Amgen is advancing MariTide, a monthly weight-loss injection, through 6 Phase 3 trials as a direct competitor to Eli Lilly and Novo Nordisk's weekly GLP-1 drugs. The product is positioned to enter the market with a convenience advantage.
Where this lands in our work
- Product Technology Executive Search →
A launch is the output of a product and engineering leadership layer built before it.
- Executive Search: Americas →
Our Americas practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record
